A phase 3 trial shows that ivarmacitinib improves symptoms in adults with moderate to severe atopic dermatitis compared with ...

Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron ...

You know that burning or crawling sensation that makes you want to scratch dry skin? It's awful—especially when it's in a ...

"Eczema, also known as atopic dermatitis, seborrheic dermatitis, and contact dermatitis frequently affect the eyelid area due ... underlying medical issue, the treatment plan is relatively simple ...

The eyelids may be the first area of the ... What is your current treatment and how long have you used these treatments? Antigens may cause dermatitis even if used only on occasion.

Pfizer sees abrocitinib and other JAK drugs coming through the pipeline for atopic dermatitis as expanding the number of patients getting treatment for the more severe end of the spectrum of ...

Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, P. R. China State Key Laboratory of ...

Belarus Atopic dermatitis (AD) is a common inflammatory skin disease. Most cases start in children although some have been reported in adults. Moderate to severe cases of AD not responding to topical ...

All products featured on Self are independently selected by our editors. However, we may receive compensation from retailers and/or from purchases of products through these links. No matter how ...

For patients with eyelid allergic contact dermatitis (ACD), a broad patch testing assessment supports optimal individualized treatment when other triggers for ACD are ruled out and routine care proves ...

This will help them determine whether a condition called myasthenia gravis is causing the droopy eyelid. The treatment for droopy eyelid depends on the specific cause and the severity of the ptosis.

Atopic dermatitis (AD) is a complex systemic disease characterized by high heterogeneity both at clinical and pathophysiology levels. While advances in drug development toward a more targeted approach ...